Therapie des Mammakarzinoms mit Augenmaß

Scharl A, Salterberg A

  1. Robert Koch Institut. (Zugriff 4.1.2016)
  2. Scharl A, Salterberg A. Multimodale Therapie des nicht metastasierten Mammakarzinoms. Onkologe  2014; 4:  379-394.
  3. Davies C, Godwin J, Gray R et al. (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
  4. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529-537.
  5. Kidwell KM, Harte SE, Hayes DF et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 2014; 120:2403-2411.
  6. Hanf V, Schütz F, Liedtke C, Thill M, on behalf of the AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015. Breast Care 2015;10:189-197
  7. AGO Kommission Mamma. Diagnostik und Therapie von Patientinnen mit primärem und metastasierten Brustkrebs.     
  8. Irwin ML, Cartmel B, Gross CP et al. Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors. J Clin Oncol. 2015;33:1104-11.
  9. Fellowes D, Fallowfield LJ, Saunders CM et al. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat. 2001;66:73-81.
  10. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 ;372:436-46. 
  11. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 ;371:107-18
  12. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26:313-20. 
  13. Scharl A. Mammographiescreening. Gynäkologe 2014; 5: 325-333.
  14. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer. Meta-analysis of surgical outcomes. Ann Surg 2013; 257:249-255.
  15. Houssami N, Turner R, Macaskill P et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrene. J Clin Oncol 2014; 32: 392-401.
  16. Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast. 2012;21:112–123.
  17. Gerber B, Seitz E, Müller H et al. Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat. 2003;82:29-37.
  18. Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012 ;30:1715-1724
  19. Rojas MP, Telaro E, Russo A, et al.  Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005 25;:CD001768
  20. Liedtke C, Thill M, Hanf V, Schütz F, on behalf of the AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014. Breast Care 2015;10:199-205
  21. Onkologisches Leitlinienprogramm. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012.
  22. Kurian AW, Lichtensztajn DY, Keegan TH et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA. 2014 ;312:902-914.
  23. Garcia-Etienne CA, Tomatis M, Heil J, et al. EeusomaDB Working Group. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer. 2012;48:1947-56.
  24. van Maaren MC, de Munck L, de Bock GH , et al. Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients, San Antonio Breast Cancer Symposium 2015 Abstract# S3-05 (Zugriff 4.1.2016)
  25. Nichols HB, Berrington de González A, Lacey JV Jr et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564-9
  26. Pilewskie M, Ho A, Orell E et al. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy. Ann Surg Oncol. 2014;21:1209-1214.
  27. Moran MS, Schnitt SJ, Giuliano AE et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507-1515.
  28. Covelli AM, Baxter NN, Fitch MI, et al. 'Taking control of cancer': understanding women's choice for mastectomy. Ann Surg Oncol. 2015;22:383-91.  
  29. Fisher CS, Martin-Dunlap T, Ruppel MB, et al. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19:3246-50
  30. Smith BD D, Jiang J, Shih Y-CT, et al. Complication and economic burden of local therapy options for early breast cancer. San Antonio Breast Cancer Symposium  2015 Abstract# S3-07 (Zugriff 4.1.2016)
  31. Peto R, Davies C, Godwin J et al. (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432-444.
  32. Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-41.
  33. Scharl A., Costa SD: Diagnostik und Therapie des duktalen Carcinoma in situ. Gynäkol prax 28 (2004) 61-79.
  34. Correa C, McGale P, Taylor C et al. (EBCTCG).  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162-177.
  35.  Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–488.
  36. Darby S, McGale P, Correa C et al. (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-1716.
  37. Schonberg MA, Marcantonio ER, Ngo L et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol. 2011 ;29:1570-1577.
  38. Hughes KS, Schnaper LA, Bellon JR et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 ;31:2382-2387.
  39. Kunkler IH, Williams LJ, Jack WJ et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266-273.
  40. Vaidya JS, Wenz F, Bulsara M et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603-13
  41. Von Minckwitz G. Reimer T, Potenberg J et al. The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. SABCS 2014 Abstract S3-04
  43. Coleman R, Powles T, Paterson A, et al: Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-61. 
  44. Rack B, Andergassen U, Neugebauer J, et al. The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel). 2010;5:395-400
  45. Goodwin PJ. Obesity and endocrine therapy: host factors and breast cancer outcome. Breast. 2013;22 Suppl 2:S44-7.
  46. Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013;22 Suppl 2:S30-7. 
  47. Chlebowski RT, Blackburn GL. Final survival analysis from the randomized Women’s Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy. San Antonio Breast Cancer Symposium  2014; Abstract S5-08.

Rationale naturheilkundliche Ansätze zur Behandlung der Primären Dysmenorrhoe

Karsten Münstedt

  1. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014; 36: 104-113. 
  2. Midilli TS, Yasar E, Baysal E. Dysmenorrhea characteristics of female students of health school and affecting factors and their knowledge and use of complementary and alternative medicine methods. Holist Nurs Pract. 2015; 29: 194-204.
  3. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ. 2006; 332: 749-755. 
  4. Abaraogu UO, Tabansi-Ochuogu CS. As Acupressure decreases pain, acupuncture may improve some aspects of quality of life for women with primary dysmenorrhea: a systematic review with meta-analysis. J Acupunct Meridian Stud. 2015; 8: 220-228.
  5. Kannan P, Claydon LS. Some physiotherapy treatments may relieve menstrual pain in women with primary dysmenorrhea: a systematic review. J Physiother. 2014; 60: 13-21. 
  6. Bakhtshirin F, Abedi S, YusefiZoj P, Razmjooee D. The effect of aromatherapy massage with lavender oil on severity of primary dysmenorrhea in Arsanjan students. Iran J Nurs Midwifery Res. 2015; 20: 156-160. 
  7. Sadeghi Aval Shahr H, Saadat M, Kheirkhah M, Saadat E. The effect of self-aromatherapy massage of the abdomen on the primary dysmenorrhoea. J Obstet Gynaecol. 2015; 35: 382-385. 
  8. Marzouk TM, El-Nemer AM, Baraka HN. The effect of aromatherapy abdominal massage on alleviating menstrual pain in nursing students: a prospective randomized cross-over study. Evid Based Complement Alternat Med. 2013; 2013: 742421.  
  9. Apay SE, Arslan S, Akpinar RB, Celebioglu A. Effect of aromatherapy massage on dysmenorrhea in Turkish students. Pain Manag Nurs. 2012; 13: 236-240. 
  10. Han SH, Hur MH, Buckle J, Choi J, Lee MS. Effect of aromatherapy on symptoms of dysmenorrhea in college students: A randomized placebo-controlled clinical trial. J Altern Complement Med. 2006; 12: 535-541.
  11. Raisi Dehkordi Z, Hosseini Baharanchi FS, Bekhradi R. Effect of lavender inhalation on the symptoms of primary dysmenorrhea and the amount of menstrual bleeding: A randomized clinical trial. Complement Ther Med. 2014; 22: 212-219.
  12. Fukui H, Toyoshima K, Komaki R. Psychological and neuroendocrinological effects of odor of saffron (Crocus sativus). Phytomedicine. 2011; 18: 726-730. 
  13. Ou MC, Hsu TF, Lai AC, Lin YT, Lin CC. Pain relief assessment by aromatic essential oil massage on outpatients with primary dysmenorrhea: a randomized, double-blind clinical trial. J Obstet Gynaecol Res. 2012; 38: 817-822. 
  14. Chung FF, Yao CC, Wan GH. The associations between menstrual function and life style/working conditions among nurses in Taiwan. J Occup Health. 2005; 47: 149-156.
  15. Witt CM, Lüdtke R, Willich SN. Homeopathic treatment of patients with dysmenorrhea: a prospective observational study with 2 years follow-up. Arch Gynecol Obstet. 2009; 280: 603-611.
  16. Eby GA. Zinc treatment prevents dysmenorrhea. Med Hypotheses. 2007; 69: 297-301. 
  17. Bronfort G, Haas M, Evans R, Leininger B, Triano J. Effectiveness of manual therapies: the UK evidence report. Chiropr Osteopat. 2010; 18: 3.
  18. Xu T, Hui L, Juan YL, Min SG, Hua WT. Effects of moxibustion or acupoint therapy for the treatment of primary dysmenorrhea: a meta-analysis. Altern Ther Health Med. 2014; 20: 33-42.
  19. Rahbar N, Asgharzadeh N, Ghorbani R. Effect of omega-3 fatty acids on intensity of primary dysmenorrhea. Int J Gynaecol Obstet. 2012; 117: 45-47. 
  20. Gokhale LB. Curative treatment of primary (spasmodic) dysmenorrhoea. Indian J Med Res. 1996; 103: 227-231. 
  21. Seifert B, Wagler P, Dartsch S, Schmidt U, Nieder J. Magnesium - eine therapeutische Alternative bei der primären Dysmenorrhoe. Zentralbl Gynakol. 1989; 111: 755-760. 
  22. Fontana-Klaiber H, Hogg B. Therapeutische Wirkung von Magnesium bei Dysmenorrhöe. Schweiz Rundsch Med Prax. 1990; 79: 491-494.
  23. Chaudhuri A, Singh A, Dhaliwal L. A randomised controlled trial of exercise and hot water bottle in the management of dysmenorrhoea in school girls of Chandigarh, India. Indian J Physiol Pharmacol. 2013; 57: 114-122.
  24. Bennink CD, Hulst LL, Benthem JA. The effects of EMG biofeedback and relaxation training on primary dysmenorrhea. J Behav Med. 1982; 5: 329-341.
  25. Halder A. Effect of progressive muscle relaxation versus intake of ginger powder on dysmenorrhoea amongst the nursing students in Pune. Nurs J India. 2012; 103: 152-156.
  26. Rakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: a randomized clinical trial. J Pediatr Adolesc Gynecol. 2011; 24: 192-196. 
  27. Navvabi Rigi S, Kermansaravi F, Navidian A, Safabakhsh L, Safarzadeh A, Khazaian S, Shafie S, Salehian T. Comparing the analgesic effect of heat patch containing iron chip and ibuprofen for primary dysmenorrhea: a randomized controlled trial. BMC Womens Health. 2012; 12: 25. 
  28. Aksoy AN, Gözükara I, Kabil Kucur S. Evaluation of the efficacy of Fructus agni casti in women with severe primary dysmenorrhea: a prospective comparative Doppler study. J Obstet Gynaecol Res. 2014; 40: 779-784. 
  29. Jenabi E, Fereidoony B. Effect of Achillea Millefolium on relief of primary dysmenorrhea: a double-blind randomized clinical trial. J Pediatr Adolesc Gynecol. 2015; 28: 402-404. 
  30. Lee HW, Jun JH, Kil KJ, Ko BS, Lee CH, Lee MS. Herbal medicine (Danggui Shaoyao San) for treating primary dysmenorrhea: A systematic review and meta-analysis of randomized controlled trials. Maturitas. 2016; 85: 19-26. 
  31. Daily JW, Zhang X, Kim da S, Park S. Efficacy of ginger for alleviating the symptoms of primary dysmenorrhea: a systematic review and meta-analysis of randomized clinical trials. Pain Med. 2015; 16: 2243-2255.

Ultraniedrig dosierte Östrogen-Therapie transdermal: Gestagen-Intervalle überdenken

J.M. Wenderlein

Literatur zu: E2 niedrigst dosiert tansdermal und Gestagen anpassen

  1. Dinh A et al: A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.Contraception 2015;91:360-367.
  2. Sriprasert I et al: Incidence of endometrial spotting or bleeding during continous-combined estrogen- progestin Therapy in postmenopausal women with or  without hypertension. Menopause2015;22:1067-75
  3. Ettinger B et al: Effects of Ultralow-Dose Transdermal Estradiol on Bone Density:A Randomized Clinical Trial Obstet Gynecol 2004;104:443-51
  4. Cummings SR et al: Endogenous hormones and the risk of hip  and vertebral fractures among older women. Study of Osteoporotic  Fractures Research Group.N Engl J Med 1998;339: 733-38
  5. Ettinger B et al: Associations between low levels of serum estradiol, bone density and fractures among elderly women: the studyof osteoporotic fractures.J ClinEndocrinol Metabol 1998;83:2239-43
  6. Peeyananjarassri K et al: Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium and the cardiovascular system: a review of randomized controlled clinical trials.Climacteric 2005;8: 13-23  
  7. NaessenT et al: Bone loss in elderly women prevented by ultralow doses of parenteral 17 beta estradiol.Am J Obstet Gynecol 1997,177:115-19
  8. Prestwood KM et al: Ultralow- dose microniced 17 beta estradiol and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-48
  9. Simon JA et al: Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomizd controlled trial.Obstet Gynecol 2007;109:588-96
  10. Mück A.O.,H.Seeger: Medikamentöse Therapiemöglichkeiten in der Menopause. Gynäkologische Endokrinologie.2011;9;151-157
  11. HebbarS et al:Factors influencing endometrial thickness in postmenopausal women. Ann Med Health Sci  Res 2014;4:608-14
  12. Fisher B. et. al: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast Cancer Project Study in  Natl Cancer J 90 (1998) 1371-1388
  13. Davis C et al Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen-receptor-positive breast cancer: ATLAS, a randomized trial. The Lancet, online Dec 5th 2012 http:/ / (12)61963-1(ATLAS= The Adjuvant Tamoxifen – Longer Against Shorter)
  14. Mück AO et al: Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application      Journal of The North American Menopause Society 2007;14:978-984
  15. Koskela-Niska V et al: Ovarian cancer risk in postmenopausal women using estradiol–progestin therapy – a  nationwide study, Climacteric, 2012;16:1, 48-53

Ist die fötale Chirurgie bei Spina Bifida ein Königsweg? Grundsätzliche Aspekte und Zürcher Erfahrungen.

Martin Meuli und Ueli Möhrlen

  1. Luthy DA, Wardinsky T, Shurtleff DB et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. NEnglJMed 1991; 324: 662-666
  2. Shurtleff D. Fetal endoscopic myelomeningocele repair. DevMed Child Neurol 2012; 54: 4-5
  3. Hutchins GM, McGowan KD, Blakemore KJ. Spinal dysraphia: not a neural tube defect? Am J Hum Genet 1992; 51: 
  4. Hutchins GM, Meuli M, Meuli-Simmen C et al. Acquired spinal cord injury in human fetuses with myelomeningocele. PediatrPatholLab Med 1996; 16: 701-712
  5. Meuli M, Meuli-Simmen C, Hutchins GM et al. The spinal cord lesion in human fetuses with myelomeningocele: implications for fetal surgery. JPediatrSurg 1997; 32: 448-452
  6. Heffez DS, Aryanpur J, Hutchins GM et al. The paralysis associated with myelomeningocele: clinical and experimental data implicating a preventable spinal cord injury. Neurosurgery 1990; 26: 987-992
  7. Meuli M, Meuli-Simmen C, Hutchins GM et al. In utero surgery rescues neurological function at birth in sheep with spina bifida. NatMed 1995; 1: 342-347
  8. Meuli M, Meuli-Simmen C, Yingling CD et al. In utero repair of experimental myelomeningocele saves neurological function at birth. JPediatrSurg 1996; 31: 397-402
  9. Meuli M, Meuli-Simmen C, Yingling CD et al. Creation of myelomeningocele in utero: a model of functional damage from spinal cord exposure in fetal sheep. JPediatrSurg 1995; 30: 1028-1032
  10. von Koch CS, Compagnone N, Hirose S et al. Myelomeningocele: characterization of a surgically induced sheep model and its central nervous system similarities and differences to the human disease. American journal of obstetrics and gynecology 2005; 193: 1456-1462
  11. Yoshizawa J, Sbragia L, Paek BW et al. Fetal surgery for repair of myelomeningocele allows normal development of the rectum in sheep. Pediatric surgery international 2003; 19: 162-166

„Irgendwoher muss es doch kommen!“ - Psychosomatischer Umgang mit chronischen Unterleibsschmerzen

Claudia Schumann

  1. Egle UT, Nickel R. Kindheitsbelastungsfaktoren bei Patienten mit somatoformen Störungen. Z Psychosom Med Psychoanal 1998; 44: 21-36
  2. Hausteiner-Wiehle C, Schäfert R, Häuser W, Herrmann M, Ronel J, Sattel H, Henningsen P (Steuerungsgruppe): S3-Leitlinie zum Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden, AWMF-Reg.-Nr. 051/ 0001,  Kurzfassung.  Stuttgart  Schattauer Verlag  2012 
  3. Hennigsen P, Zipfel S, Herzog W. Management of functional somatic syndroms. Lancet 2007; 269: 946-55
  4. Latthe P et al., WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity: systematic review. BMJ 2006b; 332,749-755
  5. Mark H et al. Gynecological symptoms associated with physical and sexual violence. J Psychosom Obstet Gynaecol 2008; 29: 164-172
  6. Meiser E.M. Rehabilitation somatoformer Schmerzen bei komorbider Posttraumatischer Belastungsstörung (PTBS).  Ärztliche Psychotherapie 2009; 4: 164-166
  7. Meltzer-Brody S et al. Trauma and posttraumatic stress disorder in women with chronic pelvic pain. Obstet Gynecol 2007; 1: 7-32
  8. Rapaehl Kg, Widom CS, Lange G. Childhood victimization and pain in adulthood: a prospective investigation. Pain 2001; 92: 283-293
  9. Schaefert R, Hausteiner-Wiehle C et alt. Klinische Leitlinie: Nicht-spezifische, funktionelle und somatoforme Körperbeschwerden. Dtsch Ärztebl 2012; 47: 803-813
  10. Siedentopf  F. Chronische Schmerzsyndrome in der gynäkologischen Praxis: Endometriose und Fibromyalgiesyndrom. Geburtsh Frauenheilk 2012;72: 1092-1098
  11. Siedentopf F, Chronischer Unterbauchschmerz. In: Weidner K, Rauchfuß M, Neises M (Hrsg.). Leitfaden psychosomatische Frauenheilkunde, Köln, Deutscher Ärzte-Verlag 2012
  12. Siedentopf F, Kölm P, Kentenich H. Chronischer Unterbauchschmerz der Frau, Leitlinie der Deutschen Gesellschaft für Psychosomatische Frauenheilkunde und Geburtshilfe  Berlin 2011, Verlag S.Kramarz

Transsexualität: Was beim Wunsch nach Geschlechtsumwandlung zu beachten ist

Prof. M. Breckwoldt, redigiert von Dr. H.U. Feldmann

  1. Jörgensen G. Transsexuellen-Gesetz verabschiedet. Münch med Wschr 1980; 122: 1785;
  2. Money J, Erhardt AA. The differentiation and dimorphism of gender identity from conception to maturity. The Johns Hopkins University Press, 1972;
  3. Breckwoldt M. Transsexualität. In: Lehrbuch für Gynäkologie und Geburtshilfe (Hrsg: M Breckwoldt, M Kaufmann, A. Fleiderer), Georg Thieme Verlag, 5. Auflage, Stuttgart 2007, Seite 12;
  4. Dörner G. Sexualhormonabhängige Gehirndifferenzierung und Sexualität, G Fischer Verlag, Jena 1992.